SeaStar Medical Holding Corporation
$4.63
▲
21.07%
2026-04-21 07:27:00
seastarmedical.com
NCM: ICU
Explore SeaStar Medical Holding Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$16.77 M
Current Price
$4.63
52W High / Low
$13.4 / $2.07
Stock P/E
—
Book Value
$2.71
Dividend Yield
—
ROCE
-116.89%
ROE
-2.95%
Face Value
—
EPS
$-5.86
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
17
Beta
-1.19
Debt / Equity
5.04
Current Ratio
3.63
Quick Ratio
3.61
Forward P/E
-1.44
Price / Sales
12.01
Enterprise Value
$3.36 M
EV / EBITDA
—
EV / Revenue
2.72
Rating
Buy
Target Price
$9
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 2. | Polyrizon Ltd. | $11.64 | — | $20.34 M | — | -27.56% | -25.38% | $2,235 / $2.88 | $13.05 |
| 3. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 4. | Veru Inc. | $2.43 | — | $39 M | — | -161.13% | -60.25% | $7.4 / $2.06 | $2.31 |
| 5. | Beam Therapeutics Inc. | $31.19 | — | $3.2 B | — | -27.72% | -8.11% | $36.44 / $15.35 | $12.48 |
| 6. | CG Oncology, Inc. | $70.4 | — | $6.2 B | — | -25.08% | -21.67% | $73.56 / $19.47 | $9.33 |
| 7. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.42 M | 0.18 M | 0.34 M | 0.29 M | 0.07 M | — |
| Operating Profit | -3.02 M | -3.58 M | -1.76 M | -3.82 M | -4.77 M | — |
| Net Profit | -2.9 M | -3.47 M | -2 M | -3.77 M | -4.42 M | — |
| EPS in Rs | -0.73 | -0.87 | -0.5 | -0.94 | -1.11 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 1.23 M | 0.14 M | 0 M | 0 M |
| Operating Profit | -12.18 M | -17.84 M | -14.21 M | -11.61 M |
| Net Profit | -12.15 M | -24.83 M | -26.23 M | -12.19 M |
| EPS in Rs | -3.04 | -6.22 | -6.57 | -3.05 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 14.16 M | 4.66 M | 3.51 M | 3.04 M |
| Total Liabilities | 3.74 M | 6.84 M | 17.38 M | 23.8 M |
| Equity | 10.42 M | -2.18 M | -13.87 M | -20.76 M |
| Current Assets | 13.58 M | 3.77 M | 2.31 M | 1.52 M |
| Current Liabilities | 3.74 M | 6.84 M | 13.05 M | 16.15 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -13.6 M | -16.01 M | -10.29 M | -7.79 M |
| Investing CF | — | — | — | — |
| Financing CF | 23.76 M | 17.65 M | 10.41 M | 7.33 M |
| Free CF | -13.6 M | -16.01 M | -10.29 M | -7.79 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 5.34% | -115.19% | — | — |
| Profit Margin % | -18392.59% | — | — | — |
| Operating Margin % | -13216.3% | — | — | — |
| Gross Margin % | 100% | — | — | — |
| EBITDA Margin % | -18209.63% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2026-01-05 | 1:0.1 |
| 2024-06-10 | 1:0.04 |